Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK/PD of JMKX003002 in Healthy Subjects
NCT05907382Phase 1Unknown
- Sponsor
- Jemincare
- Start
- May 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JMKX003002 in hyperphosphatemia (5 arms), sponsored by Jemincare. Primary endpoints: Number of Adverse Events related to single dose treatment at Day 11 and Number of Adverse Events related to multiple dose treatment at Day 18. Status: unknown.
02
Drugs
JMKX003002
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT05907382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05907382.